[HTML][HTML] SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity
…, H Ode, K Sano, TS Tan, K Imai, K Miyoshi… - Nature …, 2021 - nature.com
The causative agent of the COVID-19 pandemic, SARS-CoV-2, is steadily mutating during
continuous transmission among humans. Such mutations can occur in the spike (S) protein …
continuous transmission among humans. Such mutations can occur in the spike (S) protein …
Clinical evaluation of self-collected saliva by quantitative reverse transcription-PCR (RT-qPCR), direct RT-qPCR, reverse transcription–loop-mediated isothermal …
…, K Imai, S Tabata, K Miyoshi… - Journal of clinical …, 2020 - Am Soc Microbiol
The clinical performances of six molecular diagnostic tests and a rapid antigen test for severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were clinically evaluated for the …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were clinically evaluated for the …
[HTML][HTML] Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis
…, S Kawano, M Ikeda, T Kodama, K Miyoshi… - The Lancet Infectious …, 2020 - thelancet.com
Background The ongoing COVID-19 pandemic is a global threat. Identification of markers
for symptom onset and disease progression is a pressing issue. We described the clinical …
for symptom onset and disease progression is a pressing issue. We described the clinical …
Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19
…, S Noguchi, Y Kitagawa, M Matuoka, K Miyoshi… - Journal of clinical …, 2020 - Elsevier
Background We evaluated the clinical performance of an immunochromatographic (IC) IgM/IgG
antibody assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and …
antibody assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and …
Clinical evaluation of self-collected saliva by RT-qPCR, direct RT-qPCR, RT-LAMP, and a rapid antigen test to diagnose COVID-19
M Ikeda, K Imai, S Tabata, K Miyoshi, N Murahara… - MedRxiv, 2020 - medrxiv.org
Background The clinical performance of six molecular diagnostic tests and a rapid antigen
test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were clinically …
test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were clinically …
Antibody response patterns in COVID‐19 patients with different levels of disease severity in Japan
…, M Matsuoka, K Miyoshi… - Journal of medical …, 2021 - Wiley Online Library
We analyzed antibody response patterns according to the level of disease severity in
patients with novel coronavirus disease 2019 (COVID‐19) in Japan. We analyzed 611 serum …
patients with novel coronavirus disease 2019 (COVID‐19) in Japan. We analyzed 611 serum …
Naturally mutated spike proteins of SARS-CoV-2 variants show differential levels of cell entry
The causative agent of the coronavirus disease 2019 (COVID-19) pandemic, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), is steadily mutating during continuous …
respiratory syndrome coronavirus 2 (SARS-CoV-2), is steadily mutating during continuous …
The clinical characteristics of COVID-19: a retrospective analysis of 104 patients from the outbreak on board the Diamond Princess cruise ship in Japan
…, K Imai, S Kawano, M Ikeda, T Kodama, K Miyoshi… - MedRxiv, 2020 - medrxiv.org
Background The ongoing outbreak of the coronavirus disease 2019 (COVID-19) is a global
threat. Identification of markers for symptom onset and disease progression is a pressing …
threat. Identification of markers for symptom onset and disease progression is a pressing …
[HTML][HTML] Non-severe vs severe symptomatic COVID-19: 104 cases from the outbreak on the cruise ship “Diamond Princess” in Japan
…, K Imai, S Kawano, M Ikeda, T Kodama, K Miyoshi… - MedRxiv, 2020 - medrxiv.org
Background The ongoing outbreak of 2019 novel coronavirus disease (COVID-19) is a
global threat. Clarifying its clinical features such as risk factors for disease progression is a …
global threat. Clarifying its clinical features such as risk factors for disease progression is a …
[HTML][HTML] Cross-reactive humoral immune responses against seasonal human coronaviruses in COVID-19 patients with different disease severities
…, S Noguchi, S Takeuchi, N Arakawa, K Miyoshi… - International Journal of …, 2021 - Elsevier
Background: The cross-reactive antibody response against seasonal human coronaviruses (HCoVs)
was evaluated according to disease severity in patients with COVID-19 in Japan. …
was evaluated according to disease severity in patients with COVID-19 in Japan. …